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Background: The etiology of schizophrenia is not precisely known; however, mitochondrial function and cerebral
energy metabolism abnormalities were determined to be possible factors associated with the etiology of
schizophrenia. Impaired mitochondrial function negatively affects neuronal plasticity, and can cause cognitive
deficits and behavioral abnormalities observed during the clinical course of schizophrenia. The present study aimed
to investigate the relationship between the clinical features of schizophrenia, and mitochondrial complex activation,
based on measurement of mRNA levels in the NDUFV1, NDUFV2, NDUFS1, and UQCR10 genes involved in the
peripheral mitochondrial complex.
Methods: The study included 138 schizophrenia patients and 42 healthy controls. The schizophrenia group was
divided into a chronic schizophrenia subgroup (n = 84) and a first-episode schizophrenia subgroup (n = 54).
The symptoms profile and severity of disorder were evaluated using the Scale for the Assessment of Negative
Symptoms (SANS), Scale for the Assessment of Positive Symptoms (SAPS), and Brief Psychiatric Rating Scale (BPRS).
Results: The level of mRNA expression of NDUFV1, NDUFV2, and NDUFS1 was significantly higher in the
schizophrenia group than in the control group. The mRNA level of NDUFV2 was positively correlated with BPRS and
SAPS scores in the first-episode schizophrenia subgroup.
Conclusion: The findings showed that there was a positive correlation between gene mRNA levels and psychotic
symptomatology, especially positive symptoms. Our results suggest that mRNA levels of the NDUFV1, NUDFV2, and
NDUFS1 genes of complex I of the mitochondrial electron transport chain might become a possible peripheral
marker for the diagnosis of schizophrenia.
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levelsBackground
Schizophrenia is a chronic psychiatric disorder and its
etiology is not precisely known. A biomarker obtainable
from peripheral tissues of schizophrenia patients would
help to confirm the diagnosis and monitor its treatment.
Mitochondrial function and cerebral energy metabolism
abnormalities have been identified in patients with schi-
zophrenia [1-4]. Impaired mitochondrial function ne-
gatively affects neuronal plasticity, and causes cognitive* Correspondence: drakarsus@hotmail.com
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unless otherwise stated.deficits and behavioral abnormalities that can be observed
during the clinical course of schizophrenia [5].
Some studies that examined brain tissue in schizo-
phrenia patients reported an increase in activation of the
mitochondrial complex, as compared to controls [6,7],
whereas others reported a decrease [8,9]. Location and
function of the brain tissue examined were important in
the formation of these results. Changes in mitochondrial
complex activation in brain tissues occur based on positive
or negative symptoms of schizophrenia. For example, acti-
vation of mitochondrial complex I subunits in prefrontal
cortex neurons was low in the presence of hypofrontalityThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[9]. Variation in activation of mitochondrial complex I
in different brain regions in schizophrenia patients is
indicative of dysfunction of the pathways in the brain
in schizophrenia [9].
The mitochondrial electron transport chain (mtETC)
has been studied in an effort to find a biomarker for
schizophrenia. Ben Shachar et al. [10] observed an in-
crease in enzymatic activity of complex I in peripheral
tissues in patients with schizophrenia, as compared to
healthy controls. Dror et al. [5] reported that the ob-
served increase in activation of mitochondrial complex
I in patients with schizophrenia was associated with
psychotic symptoms. Activation of mtETC complex I
has been identified as a potential peripheral biomarker
for schizophrenia [5,10].
It is important to understand the relationship between
mitochondrial dysfunction and schizophrenia. A biomar-
ker related to mitochondrial dysfunction obtainable from
peripheral tissues in schizophrenia patients could help
confirm the diagnosis; therefore, the present study aimed
to investigate the relationship between clinical features
and mRNA levels in certain genes located in the mtETC
in schizophrenia patients.
Methods
The study included 158 male schizophrenia patients aged
20–30 years with psychotic symptoms that were followed-
up at the psychiatric clinic of a university hospital. Among
the patients, 84 had been followed-up for schizophrenia
for ≥1 year and were considered as chronic schizophrenia,
and 74 had a negative psychiatric history, but exhibited
schizophrenia-like psychotic symptoms for the first time
and were followed-up for 6 months. After the sixth month
of follow-up 54 of those 74 patients met Diagnostic and
Statistical Manual of Mental Disorders (DSM)-IV [11] cri-
teria for schizophrenia and were considered first-episode
schizophrenia; the 20 patients that did not meet the diag-
nostic criteria for schizophrenia according to DSM-IV
criteria were excluded from the study. The control group
included 42 healthy male volunteers matched for age, level
of education, and socioeconomic status. Exclusion cri-
teria were any organic disease, history of psychoactive
substance use, and use of any drug during the previous
3 months.
The study protocol was approved by the Gülhane Mili-
tary Medical Academy Ethics Committee. All of the par-
ticipants and their relatives were informed about the study
and provided written informed consent. Blood samples
were collected from the 158 patients and 42 healthy male
volunteers. All the patients underwent a diagnostic inter-
view using the Structured Clinical Interview for DSM-IV
Axis I Disorders (SCID-I) [12]. The symptoms profile and
severity of disease were evaluated using the Scale for theAssessment of Negative Symptoms (SANS), Scale for
the Assessment of Positive Symptoms (SAPS), and Brief
Psychiatric Rating Scale (BPRS). The SAPS scale consists
of 30 items. It includes hallucinations, delusions, bizarre
behavior, inappropriate affect and positive formal thought
disorders [13]. The SANS scale comprises 25 items de-
signed to assess five categories: blunted affect, alogia, ap-
athy, anhedonia, and attention [14]. Both scales have a
scoring range from 0 to 5. The BPRS assesses severity of
18 symptom constructs that are rated from 0 to 6. It
shows baseline- prognosis of disorder and therapeutic re-
sponses [15]. Two trained senior psychiatrists performed
the ratings and a consensus rating was obtained. Each of
the three scales was performed prior to initiation of drug
treatment to both groups of patients with schizophrenia.
Blood samples were collected after the implementation of
the scales on the same day. Messenger ribonucleic acid
(mRNA) levels of genes from peripheral blood samples
obtained from the participitants were investigated in the
genetic laboratory.NDUFV1, NDUFV2, NDUFS1, and UQCR10 Transcript
Expression
Total RNA was extracted from peripheral blood samples
according to standard protocols using an RNA Purifi-
cation Kit (Norgen Biotek Corp., Canada). cDNA was
synthesized from each RNA using a Transcriptor First
Strand cDNA Synthesis Kit (Roche, Germany) using
random hexamers, according to the manufacturer’s
instructions. Quantitative PCR was performed using
TaqMan probe sets (Real Time Ready Catalog Assay,
Roche, Germany) specifically designed for NDUFV1
(Assay ID: 142610), NDUFV2 (Assay ID: 125807), NDUFS1
(Assay ID: 128405), and UQCR10 (Assay ID: 132402).
The β-actin gene was used for normalization as an en-
dogenous reference gene (Assay ID: 101125). Relative
quantification was performed using Light Cycler Nano
Software v.1.0. PCR cycling conditions were 95°C for
10 min, followed by 45 cycles at 95°C for 10 s, 60°C for
30 s, and 72°C for 30 s. Each sample was run in triplicate.Statistical analysis
Descriptive data are expressed as mean ± SD (range).
Compliance with normal distribution for continuous vari-
ables was assessed via the Kolmogorov-Smirnov test. The
Kruskal-Wallis test was used for comparison of multiple
groups and the Mann–Whitney U test with Bonferroni
correction was used as an advanced binary (post hoc) test.
Comparison of the 2 groups was evaluated using the
Mann–Whitney U test. Pearson’s correlation analysis was
conducted to determine the relationship between the 2 in-
dependent variables. The level of statistical significance
was set at P < 0.05.
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Clinical characteristics
Mean age at the time of assesment in the patient group
was 22.3 ± 1.9 years (first-episode schizophrenia patients:
21.6 ± 1.5 years; chronic schizophrenia patients: 22.6 ± 3.9),
versus 22.1 ± 1.9 years in the control group (P = 0.5). There
was a significant difference in duration of disease (P < 0.01),
age at disease onset (P < 0.01), and duration of hospita-
lization (P < 0.01) between the first-episode schizophrenia
patients (n = 54) and the chronic schizophrenia patients
(n = 84) (Table 1).
mRNA levels in mitochondrial complex I genes (NDUFV1,
NDUFV2, and NDUFS1) and the complex III gene (UQCR10)
There was a significant difference in complex I gene
mRNA levels between the patients and controls, as follows:
NDUFV1 (P = 0.01), NDUFV2 (P < 0.01), and NDUFS1
(P = 0.01), whereas the UQCR10 gene (complex III)
mRNA level did not differ between the groups (P = 0.7).
There was not a significant difference in mRNA levels
of NDUFV1 (P = 0.09), NDUFV2 (P = 0.28), NDUFS1
(P = 0.32), or UQCR10 (P = 0.82) between the first-episode
schizophrenia patients and chronic schizophrenia patients.
There was a significant difference in the mRNA level of
NDUFV1 (P = 0.003), NDUFV2 (P < 0.01), and NDUFS1
(P = 0.003) between the first-episode schizophrenia pa-
tients and control subjects. There was also a significant
difference in the mRNA level of NDUFV2 (P < 0.01) be-
tween the chronic schizophrenia patients and controls
(Table 2).
The relationship between mRNA levels of mitochondrial
complex I genes (NDUFV1, NDUFV2, NDUFS1) and the
complex III gene (UQCR10), and clinical characteristics
There was a positive significant correlation between the
mRNA level of NDUFV1 and age at onset of the disease
(r = 0.21; P = 0.04), and a positive correlation between
the mRNA level of NDUFV2, and BPRS score (r = 0.31,
P = 0.03) and SAPS score (r = 0.2, P = 0.04) in the first-
episode schizophrenia patients. The schizophrenia patientsTable 1 Clinical characteristics of schizophrenia cases
Variables Groups
First-episode schizophre
Duration of disease; Mean ± s.d (month) 0.2 ± 0.1
Age of onset of the disease; Mean ± s.d (year) 21.6 ± 1.5
Duration of hospitalization; Mean ± s.d (day) 18.3 ± 3.5
SANS; Mean ± s.d 46.9 ± 11.9
SAPS; Mean ± s.d 58.7 ± 17.6
BPRS; Mean ± s.d 40.7 ± 9.4
Mean ± s.d : Mean ± standart deviation Z: Mann–Whitney U test.
No statistically significant difference was detected between first-episode schizophre
(p < 0.01) and BPRS (p < 0.01) scores were higher in first-episode schizophrenia case
(p < 0.01). Duration of hospitalization was longer in patients with first-episode schizwere also divided into subtype subgroups according to the
predominance of psychotic symptoms: paranoid (n = 32),
catatonic (n = 17), disorganized (n = 39), undifferentiated
(n = 26), and residual (n = 24). There was not a differ-
ence in gene mRNA levels between the schizophrenia
subtype subgroups (Table 3). As compared to the controls,
mRNA levels of complex I genes (NDUFV1, NDUFV2,
and NDUFS1) were significantly higher in the catato-
nic, disorganized, and undifferentiated patients (P < 0.05)
(Table 3).
Discussion
As the etiology of schizophrenia remains unclear and its
diagnosis is based on clinical criteria, there is a need for
peripheral biological markers for schizophrenia. The pre-
sent study’s findings show that there is a relationship be-
tween the clinical features of schizophrenia and the level
of expressions of mitochondrial complex I genes.
The mRNA level of mitochondrial complex genes
Activation of the mitochondrial complex was higher in
schizophrenia patients than in controls in the majority
of studies based on peripheral tissues. Such findings were
interpreted to mean that an increase in activation of
the mitochondrial complex could be considered a per-
ipheral biomarker for schizophrenia [5,10,16,17]. The
present study’s finding that increased mRNA levels of
the 75-, 51-, and 24-kDa subunits (the largest subunits
of mitochondrial complex I) in the patients with schizo-
phrenia supported the hypothesis that an increase in
activation of mitochondrial complex I might be a pos-
sible peripheral biomarker for schizophrenia. As there
was not a difference in the mRNA level of the UQCR10
gene (complex III) between the present study’s schizo-
phrenic patients and controls, and the range of UQCR10
mRNA levels was excessive, we do not consider activation
of mitochondrial complex III an appropriate biomarker
for schizophrenia.
In the present study the mRNA level of the 4 genes
that were assessed in first-episode schizophrenia patientsStatistical
analysisnia (n = 54) Chronic schizophrenia (n = 84)
32.2 ± 17.6 Z = −8.8; p < 0.01
20.2 ± 1.7 Z = −3.8; p < 0.01
14.4 ± 2.8 Z = −5.1; p < 0.01
48.2 ± 12.4 Z = −0.6; p = 0.55
39.2 ± 21.9 Z = −4.1; p < 0.01
31.0 ± 9.7 Z = −4.5; p < 0.01
nia and chronic schizophrenia in terms of SANS score (p = 0.55). SAPS
s. The age of onset of the disease was higher in first-episode schizophrenia
ophrenia cases than chronic schizophrenia cases (p < 0.01).















NDUFV1; Mean ± s.d 1.6 ± 1.3 1.3 ± 1.0 1.0 ± 0.0 Z = −1.7; 0.09 Z = −3.0; 0.003* Z = −1.4; 0.2
NDUFV2; Mean ± s.d 2.0 ± 1.6 1.8 ± 1.5 1.0 ± 0.0 Z = −1.1; 0.28 Z = −5.0; < 0.01* Z = −4.2; < 0.01*
NDUFS1; Mean ± s.d 1.6 ± 0.9 1.5 ± 1.0 1.0 ± 0.0 Z = −1.0; 0.32 Z = −3.0; 0.003* Z = −2.8; 0,07
UQCR10; Mean ± s.d 5.7 ± 13.0 5.6 ± 17.5 1.0 ± 0.0 Z = −0.2; 0.82 Z = −6.7; 0.5 Z = −1.4; 0.2
Mean ± s.d: Mean ± standart deviation *p < 0.05 Z: Mann–Whitney U test.
mRNA levels of NDUFV1 were significantly higher in first-episode schizophrenia cases than control subjects (p = 0.003). mRNA levels of NDUFV2 were significantly
higher in first-episode schizophrenia (p < 0.01) and chronic schizophrenia (p < 0.01) cases than control subjects. mRNA levels of NDUFS1 were significantly higher
in first-episode schizophrenia cases than control subjects (p = 0.003).
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but the difference was not significant. The mRNA level
of NDUFV1, NDUFV2, and NDUFS1 in the first-episode
schizophrenia patients was higher than that in the con-
trols, and the mRNA level of NDUFV2 was higher in the
chronic schizophrenia patients than in the controls. SAPS
and BPRS scores in the first-episode schizophrenia pa-
tients were higher than those in the chronic schizophrenia
patients. These data suggest that there is a positive correl-
ation between the level of gene mRNA expression and the
clinical severity of schizophrenia. The present findings are
in agreement with those of Dror et al. [5], who reported
an increase in activation of complex I in patients with
acute schizophrenia and a decrease in patients with re-
sidual schizophrenia. Dror et al.’s findings support the
hypothesis that a decrease in activation of the mitochon-
drial complex is associated with clinical improvement in
schizophrenia.
Furthermore, the mRNA level of NDUFV2 was positively
correlated with BPRS and SAPS scores in the present
study’s first-episode schizophrenia patients. The positive
correlation observed between the mRNA level of NDUFV2
and SAPS score could be considered evidence that positive
psychotic symptoms play a role in increasing the mRNA
level, which is consistent with Dror et al.’s findings [5].
The relationship between mRNA levels of the
mitochondrial complexes and clinical characteristics
There was a moderate positive correlation between the








NDUFV1; Mean ± s.d 1.4 ± 1.3 0.5 1.6 ± 0.7 0.01 1.7 ± 1.6 0.0
NDUFV2; Mean ± s.d 1.6 ± 1.2 0.2 2.1 ± 0.9 < 0.01 2.4 ± 1.9 < 0
NDUFS1; Mean ± s.d 1.3 ± 0.8 0.4 1.9 ± 1.0 0.01 1.7 ± 0.8 0.0
UQCR10; Mean ± s.d 5.6 ± 13.5 0.6 12.9 ± 21.5 0.1 2.6 ± 4.2 0.7
Mean ± s.d: Mean ± standart deviation X2: Kruskal Wallis test pa : Compared with con
There was no significant difference in mRNA levels of schizophrenia subtypes. mRN
disorganized and undifferentiated types were significantly higher than control groupresent study patients of a particular age range were se-
lected based on the potential effect of age on gene mRNA
levels. Age at onset of disease in the present study’s schi-
zophrenia patients was 17–26 years, and it was considered
inappropriate to assess the relationship between gene
mRNA levels and age at disease onset in this group; to
properly evaluate this relationship comparison of gene
mRNA levels in schizophrenia patients with early-onset
and late-onset of symptoms would be more appropriate.
In the present study, a relationship between gene mRNA
levels and duration of illness was not observed. As mRNA
levels were similar in the first-episode and chronic schizo-
phrenia patients, this finding is consistent with the com-
parison of first-episode and chronic schizophrenia patients
with regard to gene mRNA levels. There were not any dif-
ferences in the present study in gene mRNA levels of the
genes according to the schizophrenia subtypes; this lack of
difference supports the notion that the findings might re-
flect psychopathology of schizophrenia. Nonetheless, there
were significant differences in mRNA levels of complex I
genes between the controls, and the catatonic, disorga-
nized, and undifferentiated subtype subgroups, whereas
there was not a difference between the controls, and the
paranoid or residual subtype subgroups. To the best
our knowledge the present study is the first to compare
mitochondria complex gene mRNA levels according to
schizophrenia clinical subtypes. In paranoid and residual
subtypes, behavioral pathologies, such as disorganized or
catatonic expected to be less than the other types [11].






2 1.5 ± 1.2 0.02 1.3 ± 0.6 0.08 X 2 = 3.50; df = 2; p = 0.5
.01 1.7 ± 1.1 0.02 1.6 ± 1.8 0.1 X 2 = 5.48; df = 2; p = 0.2
1 1.6 ± 0.7 < 0.01 1.5 ± 1.2 0,.2 X 2 = 4.10; df = 2; p = 0.4
1.8 ± 2.2 0.7 9.7 ± 24.8 0.2 X 2 = 2.5; df = 2; p = 0.6
trol group.
A levels of complex I genes (NDUFV1, NDUFV2, NDUFS1) in catatonic,
p.
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mon could be interpreted as there was a relationship
between behavioral pathology and mRNA levels in schi-
zophrenia, which is supported by earlier reports that
changes in activation of the mitochondrial complex in
neuronal cells leads to behavioral symptoms that cause
abnormal neuronal transmission and synaptic plasticity
[5,9,18-21].
Limitations
Damage formation in mitochondrial structures increases
with age [22-26]. The present study included schizo-
phrenia patients aged 20–30 years, so as to avoid the
confounding effects of age. Although the literature con-
tains no data, only male patients were selected due to
the possibility that gender might affect gene mRNA
levels. Additional studies that compare changes in acti-
vation of the mitochondrial complex according to gen-
der and age are warranted.
The first-episode schizophrenia patients in the present
study were drug naïve, but the chronic schizophrenia pa-
tients had a history of antipsychotic drug use. Various ef-
fects of antipsychotics on mtETC have been reported
[27-32]. Positive history of antipsychotic drug use might
have effects on gene mRNA levels. To minimize this pos-
sibility, the present study’s chronic schizophrenia patients
did not use any drug for 3 months prior to beginning the
study.
Conclusions
In conclusion, the present findings indicate that mRNA
levels of complex I genes located in the mtETC might
become a possible peripheral marker for the diagnosis of
schizophrenia. Additionally, the findings show that there
was a positive correlation between gene mRNA levels
and psychotic symptomatology, especially positive symp-
toms. Long-term follow-up of schizophrenia patients to
monitor changes in gene mRNA levels during different
episodes of schizophrenia could help to clarify the etio-
pathogenesis of schizophrenia. Likewise, studies that
compare changes in gene mRNA levels in schizophrenia
patients that do and do not respond to drug treatment
might further elucidate the disease’s etiology and the
usefulness of activation of the mitochondrial complex as
a biomarker for schizophrenia.
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